Cardiology

The secondary SOUL trial analysis shows oral semaglutide reduces heart failure events in patients with diabetes and pre-existing heart failure.

Performance on the one-minute sit-to-stand test was a strong predictor of prognosis. Each additional repetition was associated with a lower risk of adverse outcomes (hazard ratio: 0.94; 95% CI: 0.90–0.98; p

The newly developed AI tool, known as ONCO-ACS, was designed specifically to predict six-month mortality, major bleeding, and ischaemic events in patients with cancer and acute coronary syndrome.

The study reported that 40.1% of patients with AF had either large non-cortical and cortical infarcts or small non-cortical infarcts, compared with 24.0% of patients without AF.

Those exposed to early-life sugar rationing had an approximately 14% lower risk of developing heart failure and were diagnosed an average of 2.6 years later than individuals who were unexposed.

Those with ASCVD were more likely to experience somatic symptoms (OR 1.138; 95% CI 1.069–1.212), anxiety and insomnia (OR 1.113; 95% CI 1.043–1.188), and severe depression (OR 1.173; 95% CI 1.084–1.269).

MPO concentrations in selectively drained pericardial fluid were 25-fold higher than mixed drainage samples and 1,648-fold higher than serum levels (both p

Overexpression of hsa-miR-339-5p suppressed NLRC5, activated the PI3K/Akt signalling pathway, and significantly increased type 1 collagen and α-smooth muscle actin expression, indicating enhanced fibrotic remodelling.